Swiss Life Asset Management Ltd Sells 2,828 Shares of Elevance Health, Inc. $ELV

Swiss Life Asset Management Ltd reduced its position in shares of Elevance Health, Inc. (NYSE:ELV) by 6.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 39,799 shares of the company’s stock after selling 2,828 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Elevance Health were worth $13,952,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Murphy Middleton Hinkle & Parker Inc. acquired a new stake in shares of Elevance Health during the fourth quarter worth $5,941,000. Evergreen Wealth Management LLC grew its stake in shares of Elevance Health by 33.5% in the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock valued at $5,584,000 after acquiring an additional 4,336 shares in the last quarter. Blume Capital Management Inc. increased its position in Elevance Health by 236.7% during the third quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after acquiring an additional 4,320 shares during the period. Victory Capital Management Inc. raised its stake in Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after purchasing an additional 109,462 shares in the last quarter. Finally, Caprock Group LLC acquired a new stake in Elevance Health in the 3rd quarter worth about $1,638,000. 89.24% of the stock is currently owned by institutional investors.

Elevance Health Price Performance

ELV stock opened at $381.58 on Tuesday. The company’s 50-day moving average price is $315.03 and its two-hundred day moving average price is $332.51. The firm has a market cap of $82.86 billion, a P/E ratio of 16.23, a P/E/G ratio of 2.15 and a beta of 0.66. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $424.24.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts anticipate that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.8%. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft increased their target price on shares of Elevance Health from $332.00 to $363.00 and gave the stock a “hold” rating in a research report on Thursday, April 23rd. Robert W. Baird lifted their price target on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Truist Financial cut their price target on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Leerink Partners set a $364.00 price target on Elevance Health in a research report on Thursday, April 23rd. Finally, Bank of America upgraded Elevance Health from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $405.00 to $435.00 in a research note on Wednesday, April 29th. Thirteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $384.58.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.